GH
Guardant Health·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Hanging Man
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GH
Guardant Health, Inc.
A leading precision oncology company that provides non-invasive cancer testing and analytics
Biological Technology
--
10/04/2018
NASDAQ Stock Exchange
1,999
12-31
Common stock
3100 Hanover Street, Palo Alto, California, 94304
--
Guardant Health, Inc., was incorporated in Delaware in December 2011. The company is a leading precision oncology company dedicated to helping the world conquer cancer through the use of its proprietary blood tests, extensive datasets and advanced analysis. Guardant Health, Inc., believes that the key to conquering cancer is unprecedented access to its molecular information at all stages of the disease, which they intend to achieve through routine blood draws or liquid biopsies. Guardant Health Guardant Health Oncology Platform aims to leverage its capabilities in technology, clinical development, regulation and reimbursement to drive commercial applications, improve patient clinical outcomes and reduce healthcare costs. In order to achieve their goal of managing cancer at all stages of the disease, the company has launched their liquid biopsy tests, Guardant 360 and Guardant OMNI, for the treatment of advanced cancer, to power the company's program of recurrence and early detection testing, LUNAR-1 and LUNAR-2, respectively.
Earnings Call
Q1/2025
Estimate EPS-0.59
Actual EPS-0.49
Estimate Revenue190.00M
Actual Revenue203.50M
Guardant Health's Q1 2025: Unraveling Contradictions in Shield Volume, Reveal Growth, and Medicare Coverage
May 09,2025 03:40
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.51
Actual EPS-0.44
Estimate Revenue211.28M
Actual Revenue232.10M
Guardant Health's Q2 2025: Unpacking Contradictions in Volume Growth, Medicaid Impact, and Market Strategy
Jul 31,2025 11:24
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.49
Actual EPS-0.39
Estimate Revenue235.69M
Actual Revenue265.20M
Guardant Health's Q3 2025: Contradictions Emerge on Shield ASP, Reveal Test Frequency, and Oncology Growth Strategy
Oct 30,2025 02:27
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
GH has released its 2025 Q3 earnings. EPS was reported at -0.39, versus the expected -0.49, beating expectations. The chart below visualizes how GH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GH has released its 2025 Q3 earnings report, with revenue of 265.20M, reflecting a YoY change of 38.50%, and net profit of -92.72M, showing a YoY change of 13.95%. The Sankey diagram below clearly presents GH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
